Staff Members - Benha University
Lipoprotein (A) In Type 2 Diabetes Mellitus as A Marker of Atherosclerotic Cardiovascular Disease
• 2022
Publication Information
Authors
Amira M. Elsayed*, Rasha O. Abdelmoniem, Hend R. Aboelfotouh, Walaa M. lbrahim
Keywords
Lipoprotein (a), Diabetes Mellitus, HbA1c, ASCVD, case control study.
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background: One of the most important complications of Type 2 diabetes mellitus (T2DM) is atherosclerotic cardiovascular disorders (ASCVD), a disease that affects a large percentage of the population and considered a healthcare burden. Objective: Our aim to establish a probable relationship between lipoprotein (a) [Lp (a)] and T2DM and to demonstrate it as a marker of (ASCVD).
Patients and Methods: This case-control study included 200 subjects; 150 diabetic patients and 50 age and gender matched healthy subjects. Thorough history taking of T2DM with assessment of vascular diabetic complications was done. The fasting plasma glucose, HbA1c, lipid profile, s. creatinine and Lp (a) level were performed to all participants.
Results: Lp (a) levels were significantly low in diabetic patients (19.8 ± 13.4 mg/dl) compared to control group (32.6 ± 20.8 mg/dl) (p
Patients and Methods: This case-control study included 200 subjects; 150 diabetic patients and 50 age and gender matched healthy subjects. Thorough history taking of T2DM with assessment of vascular diabetic complications was done. The fasting plasma glucose, HbA1c, lipid profile, s. creatinine and Lp (a) level were performed to all participants.
Results: Lp (a) levels were significantly low in diabetic patients (19.8 ± 13.4 mg/dl) compared to control group (32.6 ± 20.8 mg/dl) (p